Glen­mark launches Akynzeo in Nepal, In­dia

BioSpectrum (India) - - WORLD NEWS -

Glen­mark Phar­ma­ceu­ti­cals has launched Akynzeo, a drug used for preven­tion of chemother­a­pyin­duced nau­sea and vom­it­ing, in In­dia and Nepal un­der an ex­clu­sive li­cens­ing pact with Swiss pharma group, Helsinn.

Akynzeo is an oral fixed com­bi­na­tion of ne­tupi­tant 300 mg and palonosetron 0.5 mg. It is ad­min­is­tered in a sin­gle cap­sule and of­fers 5-day pro­phy­laxis from of both acute and de­layed phases of chemo­ther­apy-in­duced nau­sea and vom­it­ing (CINV).

The drug is al­ready be­ing mar­keted in the EU, the US, and sev­eral other lead­ing mar­kets of the world. The prod­uct has been de­vel­oped by Helsinn, and Glen­mark has ex­clu­sive mar­ket­ing rights for it in In­dia and Nepal.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.